(10S,11R,12R)-12-羟基-6,6,10,11-四甲基-4-丙基-11,12-二氢-2H,6H,10H-二吡喃并[2,3-f:2',3'-h]色烯-2-酮 | 163661-45-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: (10S,11R,12R)-12-羟基-6,6,10,11-四甲基-4-丙基-11,12-二氢-2H,6H,10H-二吡喃并[2,3-f:2',3'-h]色烯-2-酮
• 英文名称: (+/-)-Calanolide A
• 英文别名: (16S,17R,18R)-18-hydroxy-10,10,16,17-tetramethyl-6-propyl-3,9,15-trioxatetracyclo[12.4.0.02,7.08,13]octadeca-1(14),2(7),5,8(13),11-pentaen-4-one
• CAS: 163661-45-8
• 化学式: C₂₂H₂₆O₅
• 分子量: 370.445
• InChiKey: NIDRYBLTWYFCFV-OAVHHTNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (10S,11R,12R)-12-羟基-6,6,10,11-四甲基-4-丙基-11,12-二氢-2H,6H,10H-二吡喃并[2,3-f:2',3'-h]色烯-2-酮 在 jones reagent 作用下， 以 丙酮 为溶剂， 生成 (10R,11R)-10,11-dihydro-4-propyl-6,6,10,11-tetramethyl-2H,6H,12H-benzo[1,2-b;3,4-b';5,6-b'']tripyran-2,12-dione
  参考文献：
  名称：

  Structure−Activity Modifications of the HIV-1 Inhibitors (+)-Calanolide A and (−)-Calanolide B

  摘要：

  The Delta(7,8) olefinic linkages within (+)-calanolide A (1) and (-)-calanolide B (2) were catalytically reduced to determine impact on the anti-HIV activity of the parent compounds. In addition, a series of structure modifications of the C-12 hydroxyl group in (-)-calanolide B was made to investigate the importance of that substituent to the HIV-1 inhibitory activity of these coumarins. A total of 14 analogs were isolated or prepared and compared to (+)-calanolide A and (-)-calanolide B in the NCI primary anti-HIV assay. While none of the compounds showed activity superior to the two unmodified leads, some structure-activity requirements were apparent from the relative anti-HIV potencies of the various analogs.

  DOI：

  10.1021/jm9602827
• 作为产物：
  描述：

  5-Hydroxy-2,2-dimethyl-6-(2-methylbutanoyl)-10-propyl-2H,8H-benzo<1,2-b:3,4-b'>dipyran-8-one 在 sodium hydroxide 、 sodium tetrahydroborate 、 氢溴酸 、 溴 、 potassium hydrogen phthalate 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 magnesium iodide 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 二氯甲烷 、 丙酮 、 苯 为溶剂， 反应 2.33h， 生成 (10S,11R,12R)-12-羟基-6,6,10,11-四甲基-4-丙基-11,12-二氢-2H,6H,10H-二吡喃并[2,3-f:2',3'-h]色烯-2-酮
  参考文献：
  名称：

  Palmer, Christopher; Josephs, Jonathan, Journal of the Chemical Society. Perkin transactions I, 1995, # 24, p. 3135 - 3152

  摘要：

  DOI：

文献信息

• Synthesis, Chromatographic Resolution, and Anti-Human Immunodeficiency Virus Activity of (±)-Calanolide A and Its Enantiomers
  作者：Michael T. Flavin、John D. Rizzo、Albert Khilevich、Alla Kucherenko、Abram K. Sheinkman、Vilayphone Vilaychack、Lin Lin、Wei Chen、Eugenia Mata Greenwood、Thitima Pengsuparp、John M. Pezzuto、Stephen H. Hughes、Thomas M. Flavin、Michael Cibulski、William A. Boulanger、Robert L. Shone、Ze-Qi Xu

  DOI：10.1021/jm950797i

  日期：1996.3.15

  synthesized in a five-step approach starting with phloroglucinol [-->5-->6-->11-->18-->(+/-)-1], which includes Pechmann reaction, Friedel-Crafts acylation, chromenylation with 4,4-dimethoxy-2-methylbutan-2-ol, cyclization, and Luche reduction. Cyclization of chromene 11 to chromanone 18 was achieved by employing either acetaldehyde diethyl acetal or paraldehyde in the presence of trifluoroacetic acid

  以邻苯三酚[-> 5-> 6-> 11-> 18->（+ /-）-1]，其中包括Pechmann反应，Friedel-Crafts酰化，用4,4-二甲氧基-2-甲基丁烷-2-醇进行的苯甲酰化，环化和Luche还原。在三氟乙酸和吡啶或PPTS存在下，通过使用乙醛二乙缩醛或对甲醛，将色烯11环化为苯并二氢吡喃酮18。在较低温度下卢切还原苯并二氢吡喃酮18优选产生（+/-）-1。由色烯11通过Kostanecki-Robinson反应合成的色酮12的还原不能提供（+/-）-1。合成的（+/-）-1已色谱分离成其光学活性形式（+）-和（-）-1。合成（+/-）-1的抗HIV活性，以及合成的（+）-和（-）-1已确定。只有（+）-1表示抗HIV活性，这与报道的天然产物数据相似，而（-）-1没有活性。
• Method and composition for treating and preventing mycobacterium infections
  申请人：Sarawak Medichem Pharmaceuticals, Inc.

  公开号：US20010027209A1

  公开（公告）日：2001-10-04

  Calanolides and analogues thereof that demonstrate potent mycobacterium activity are provided. Also provided is a method of using calanolides and analogues thereof for treating or preventing mycobacterium infections. The calanolides and analogues thereof provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.

  提供了具有强效分枝杆菌活性的卡那洛利德及其类似物。还提供了一种使用卡那洛利德及其类似物治疗或预防分枝杆菌感染的方法。所提供的卡那洛利德及其类似物是通过使用色慕4和色酮7作为关键中间体合成而得到的。
• Calanolide analogues and methods of their use
  申请人：Sarawak Medichem Pharmaceuticals,Inc.

  公开号：US20020013478A1

  公开（公告）日：2002-01-31

  Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.

  本文提供了表现出对许多病毒具有强效抗病毒活性的Calanolide类似物。还提供了使用Calanolide类似物治疗或预防病毒感染的方法。所提供的Calanolide类似物是通过使用柿蒂素4和柿酮7作为关键中间体进行合成获得的。
• Method for the preparation of (.+-.)-calanolide A and intermediates
  申请人：Sarawak MediChem Pharmaceuticals, Inc.

  公开号：US06043271A1

  公开（公告）日：2000-03-28

  A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (.+-.)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing a viral infections using (.+-.)-calanolide or (-)-calanolide is provided.

  提供了一种从香豆素4制备(.+-.)-calanolide A、1，一种有效的HIV反转录酶抑制剂的方法。还提供了制备(.+-.)-calanolide A及其衍生物的有用中间体。根据公开的方法，将香豆素4中间体与乙二醇醚乙醛或对乙醛在酸催化剂存在下加热反应，或者在酸性条件或中性Mitsunobu条件下进行醛缩反应和环化的两步反应，制备出香豆酮7。在三氯化铈存在下，用氢化钠还原香豆酮7，制备出(.+-.)-calanolide A。还公开了通过手性HPLC系统或酶促酰化和水解将(.+-.)-calanolide A分离成其光学活性形式的方法。最后，提供了使用(.+-.)-calanolide或(-)-calanolide治疗或预防病毒感染的方法。
• Method for the preparation of aldol product 7B
  申请人：Sarawak MediChem Pharmaceuticals, Inc.

  公开号：US05840921A1

  公开（公告）日：1998-11-24

  A method of preparing (.+-.)-calanolide A, 1, a potent HIV reverse transcriptase inhibitor, from chromene 4 is provided. Useful intermediates for preparing (+)-calanolide A and its derivatives are also provided. According to the disclosed method, chromene 4 intermediate was reacted with acetaldehyde diethyl acetal or paraldehyde in the presence of an acid catalyst with heating, or a two-step reaction including an aldol reaction with acetaldehyde and cyclization either under acidic conditions or neutral Mitsunobu conditions, to produce chromanone 7. Reduction of chromanone 7 with sodium borohydride, in the presence of cerium trichloride, produced (.+-.)-calanolide A. A method for resolving (.+-.)-calanolide A into its optically active forms by a chiral HPLC system or by enzymatic acylation and hydrolysis is also disclosed. Finally, a method for treating or preventing viral infections using (.+-.)-calanolide A or (-)-calanolide A is provided.

  提供了一种从柿蒲素4制备(.+-.)-卡拉诺利德A，1，一种有效的HIV反转录酶抑制剂的方法。还提供了用于制备(+)-卡拉诺利德A及其衍生物的有用中间体。根据所披露的方法，柿蒲素4中间体在加热的酸催化剂存在下与乙二醇缩醛或对缩醛反应，或在酸性条件或中性Mitsunobu条件下进行的醛缩反应和环化的两步反应中，生成柿蒲酮7。在三氯化铈存在下，用硼氢化钠还原柿蒲酮7，生成(.+-.)-卡拉诺利德A。还公开了一种通过手性HPLC系统或通过酶促酰化和水解将(.+-.)-卡拉诺利德A分离为其光学活性形式的方法。最后，提供了一种使用(.+-.)-卡拉诺利德A或(-)-卡拉诺利德A治疗或预防病毒感染的方法。